Page 2 - ப்ரூக்கர் நிறுவனம் நாஸ்டாக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ரூக்கர் நிறுவனம் நாஸ்டாக். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ரூக்கர் நிறுவனம் நாஸ்டாக் Today - Breaking & Trending Today

Bruker and Evosep Announce Major Progress in Unbiased, Quantitative True Single-cell Proteomics

Press release content from Business Wire. The AP news staff was not involved in its creation.
Bruker and Evosep Announce Major Progress in Unbiased, Quantitative True Single-cell Proteomics
January 5, 2021 GMT
Figure 1: Evosep One LC and timsTOF Pro MS (Photo: Business Wire)
BILLERICA, Mass. & ODENSE, Denmark (BUSINESS WIRE) Jan 5, 2021
Bruker Corporation (Nasdaq: BRKR) and Evosep today announced major progress in high-sensitivity, quantitative true single-cell proteomics, using a modified
timsTOF Pro mass spectrometer connected to an
Evosep One low-flow chromatography system.
Figure 1: Evosep One LC and timsTOF Pro MS (Photo: Business Wire)
These advances have been demonstrated by the Mann-group in a paper by ....

United States , Miroslava Minkova , Matthias Mann , Christian Ravnsborg , Nicolai Bache , Gary Kruppa , Petra Scheffer , Bruker Daltonics Marketing Communications , Investor Relations Corporate Development , Bruker Corporation , Bruker Corporation Nasdaq , Max Planck Institute Of Biochemistry , Evosep One , Business Wire , Professor Matthias Mann , Max Planck Institute , Vice President , Bruker Media Contact , Investor Contact , Investor Relations , Media Contact , Western Europe , ஒன்றுபட்டது மாநிலங்களில் , மத்தியாஸ் மான் , நிகோலாய் பச்செ , கேரி கிருப்பா ,

Bruker Launches FluoroType® SARS-CoV-2/Flu/RSV PCR Panel in Europe with CE-IVD Mark

Published: Dec 18, 2020
NEHREN, Germany (BUSINESS WIRE) Bruker Corporation (Nasdaq: BRKR) today announced the launch of the
FluoroType SARS-CoV-2/Flu/RSV winter four-plex PCR panel, which enables the sensitive and simultaneous detection of the SARS-CoV-2 virus, of both influenza A and B viruses, as well as of the respiratory syncytial virus (RSV). In the winter season, multiple viruses need to be differentiated in one assay to facilitate diagnosis and patient management.
Figure 1: FluoroType SARS-CoV-2/Flu/RSV Test Kit (Photo: Business Wire)
The
FluoroType SARS-CoV-2/Flu/RSV panel is CE-IVD labelled according to European IVD Directive (98/79/EC). It has been validated for nasopharyngeal swabs, oropharyngeal swabs and saliva samples. The kit includes all reagents to generate up to 96 PCR result panels in under two hours after nucleic acid extraction. In evaluations, the sensitivity and specificity from 112 nasopharyngeal or oropharyngeal swabs have achie ....

Wolfgang Pusch , Bruker Daltonics , Hain Lifescience Gmb , Health Care Center , Bruker Corporation Nasdaq , Business Wire , Steffi Czieschnek , Medical Healthcare Center , Clinical Chemistry , Executive Vice President Microbiology , Hain Diagnostics , Molecular Diagnostics , Lifescience Gmbh , Bruker Corporation , ஓநாய் தள்ளு , ஹெய்ன் ஆயுள் அறிவியல் க்ம்ப் , ஆரோக்கியம் பராமரிப்பு மையம் , ப்ரூக்கர் நிறுவனம் நாஸ்டாக் , வணிக கம்பி , மருத்துவ சுகாதாரம் மையம் , மருத்துவ வேதியியல் , நிர்வாகி துணை ப்ரெஸிடெஂட் நுண்ணுயிரியல் , ஹெய்ன் பரிசோதனை , மூலக்கூறு பரிசோதனை , ஆயுள் அறிவியல் கஂப் , ப்ரூக்கர் நிறுவனம் ,

Bruker Corporation: Bruker Launches FluoroType SARS-CoV-2/Flu/RSV PCR Panel in Europe with CE-IVD Mark

Bruker Corporation: Bruker Launches FluoroType SARS-CoV-2/Flu/RSV PCR Panel in Europe with CE-IVD Mark
Validation with nasopharyngeal swabs and oropharyngeal swabs for highest sensitivity
Saliva sampling option convenient for patients, while also achieving high PCR sensitivity; saliva samples do not require extraction and enable a faster, resource-effective workflow
Bruker Corporation (Nasdaq: BRKR) today announced the launch of the
FluoroType SARS-CoV-2/Flu/RSV winter four-plex PCR panel, which enables the sensitive and simultaneous detection of the SARS-CoV-2 virus, of both influenza A and B viruses, as well as of the respiratory syncytial virus (RSV). In the winter season, multiple viruses need to be differentiated in one assay to facilitate diagnosis and patient management. ....

Miroslava Minkova , Wolfgang Pusch , Bruker Genoxtract , Bruker Daltonics , Philip Perry , Hain Lifescience Gmb , Corporate Development , Health Care Center , Bruker Corporation Nasdaq , Respiratory Syncytial Virus , Business Wire , Steffi Czieschnek , Medical Healthcare Center , Clinical Chemistry , Executive Vice President Microbiology Diagnostics , Hain Diagnostics , Molecular Diagnostics , Microbiology Diagnostics , Lifescience Gmbh , Bruker Corporation , Investor Relations , ஓநாய் தள்ளு , பிலிப் பெர்ரி , ஹெய்ன் ஆயுள் அறிவியல் க்ம்ப் , பெருநிறுவன வளர்ச்சி , ஆரோக்கியம் பராமரிப்பு மையம் ,